VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
0 hedge funds and large institutions have $0 invested in VALEANT PHARMACEUTICALS INTL in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $1.46M → $0 (-$1.46M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cullinan Associates
Louisville,
Kentucky
|
-$1.08M |
| 2 |
BBI
Baxter Bros Inc
Riverside,
Connecticut
|
-$370K |
| 3 |
SIM
Sonora Investment Management
Tucson,
Arizona
|
-$8K |
VRX Hedge Fund Activity: Q3 2018 in Review
0 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q3 2018, worth a combined $0 — down 100% from $1.46M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VRX and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Cullinan Associates, exiting entirely with an estimated $1.08M sold.
- 0 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q3 2018, down from 3 in Q2 2018.
- Funds reported $0 of VALEANT PHARMACEUTICALS INTL stock for Q3 2018, down 100% quarter-over-quarter.
- 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q3 2018 and 3 closed out, a net change of -3 holders.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q3 2018 was Cullinan Associates, an estimated $1.08M sold.
Based on aggregated 13F filings for Q3 2018.